Citoxlab and Charles River Laboratories entered today into exclusive discussions
We are pleased to inform you that Charles River Laboratories International, Inc. (NYSE: CRL) and Citoxlab have entered today into exclusive discussions pursuant to an exclusivity agreement for the intended acquisition of Citoxlab by Charles River. The proposed transaction would be expected to close in the second quarter of 2019, subject to labor consultations and regulatory requirements.
Citoxlab California Symposia
Preliminary agenda now available! May 7th and May 9th 2019
This symposium will discuss regulatory strategies along with non-clinical case studies involving NCE and biologics. An opportunity to network with non-clinical experts and discuss toxicology, pharmacology and regulatory science.
Webinar – Extended One-Generation Reproductive Toxicity Study
Extended One-Generation Reproductive Toxicity Study – Webinar
Thanks to a solid expertise in Developmental and Reproductive Toxicology, Citoxlab has the experience and know-how required for managing such a complex study and has already built a robust Historical Control Dataset.
Prepare your regulatory submissions
Discover our customized packages and benefit from our unique expertise in nose-only and oro-nasal exposure.
Discover our growing portfolio of more than 200 biomarkers
Explore our translational science expertise through highly relevant preclinical and clinical biomarkers platforms.
Find out more: ELISA, ELISPOT, Functional assays, Flow cytometry and activation testing, Multiplex analysis, qPCR, genomics, etc.
DART: New non-rodent models
Work with our science-driven teams
Multispecies early to late developmental assessment /
ePPND studies in rabbits for vaccines and biotech-derived products /
EFD studies in non-human primates.